Further, it has been shown that hypercholesterolemia, hypertriglyceridemia, and cognitive effects were more frequently observed with lorlatinib than with crizotinib (targets: ALK/ROS1),28 suggesting that these side effects may be caused by off‐target inhibition of lorlatinib. This evidence concerns the gene ALK and familial hypercholesterolemia.